- Home
- NFBK vs MREO Comparison
NFBK vs MREO Comparison
Compare NFBK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFBK
- MREO
- Stock Information
- Founded
- NFBK 1887
- MREO 2015
- Country
- NFBK United States
- MREO United Kingdom
- Employees
- NFBK N/A
- MREO N/A
- Industry
- NFBK Major Banks
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- NFBK Finance
- MREO Health Care
- Exchange
- NFBK Nasdaq
- MREO Nasdaq
- Market Cap
- NFBK 406.5M
- MREO 438.8M
- IPO Year
- NFBK 2007
- MREO N/A
- Fundamental
- Price
- NFBK $12.22
- MREO $2.89
- Analyst Decision
- NFBK Buy
- MREO Strong Buy
- Analyst Count
- NFBK 2
- MREO 5
- Target Price
- NFBK $13.00
- MREO $7.60
- AVG Volume (30 Days)
- NFBK 210.0K
- MREO 1.2M
- Earning Date
- NFBK 07-23-2025
- MREO 08-12-2025
- Dividend Yield
- NFBK 4.26%
- MREO N/A
- EPS Growth
- NFBK 1.58
- MREO N/A
- EPS
- NFBK 0.76
- MREO N/A
- Revenue
- NFBK $128,407,000.00
- MREO N/A
- Revenue This Year
- NFBK $12.68
- MREO N/A
- Revenue Next Year
- NFBK $15.15
- MREO $52.34
- P/E Ratio
- NFBK $16.06
- MREO N/A
- Revenue Growth
- NFBK N/A
- MREO N/A
- 52 Week Low
- NFBK $8.92
- MREO $1.58
- 52 Week High
- NFBK $14.39
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- NFBK 59.51
- MREO 61.42
- Support Level
- NFBK $11.39
- MREO $2.63
- Resistance Level
- NFBK $12.17
- MREO $2.94
- Average True Range (ATR)
- NFBK 0.39
- MREO 0.15
- MACD
- NFBK 0.02
- MREO -0.00
- Stochastic Oscillator
- NFBK 85.83
- MREO 79.41
About NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).